Revance Therapeutics Total Liabilities

Revance Therapeutics's total liabilities stands at $620M as of September 2024. That compares with $640M in the prior-year period — down 2.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Revance Therapeutics reported $620M in total liabilities versus $640M a year earlier — a 2.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $640M in the prior-year period — down 2.2% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Revance Therapeutics's total liabilities evolved across reporting periods, while the comparison chart places RVNC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Revance Therapeutics's reading of $620M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.